Multiple Sclerosis Centers of Excellence
Multiple Sclerosis Medications and Interventions
Treatments for MS focus on controlling the immune system and managing symptoms. The current goals for MS care are to reduce the frequency of relapses and to slow the progression of the disease by using a drug therapy approach called disease modifying treatments (DMTs). In addition to the use of a DMT, it is important for people to work with their health care providers to find the best approach to address MS symptoms like extreme fatigue, bladder problems and muscle spasms. MS symptoms can be managed with conventional medication, complementary and alternative medicine, physical therapy, mobility devices, and other self-care approaches.
VA healthcare providers can request a patient consultation from MSCoE for Veterans who are enrolled for VA health care benefits. For information please visit our remote consults page.
- MSCoE Approach to Generic and Biosimilar Disease Modifying Therapies
- MSCoE Consensus Statement: Relapse and Disease Management in MS
- MSCoE Pocket Reference for MS Disease Modifying Therapies
- VA Formulary Advisor
- VA Pharmacy Benefits Management: Adverse Drug Event Reporting System
- VA Pharmacy Benefits Management: Clinical Guidance (VA access only)
- VA Pharmacy Benefits Management: Criteria for Use (VA access only)
- VA Pharmacy Benefits Management: Drug Monographs (VA access only)
- Glatiramer Acetate (Copaxone, Glatopa, Glatiramer Acetate Injection)
- Interferon Beta-1a (Avonex)
- Interferon Beta-1a (Rebif)
- Interferon Beta-1b (Betaseron, Extavia)
- Ofatumumab (Kesimpta)
- Peginterferon Beta-1a (Plegridy)
- Cladribine (Mavenclad)
- Dimethyl Fumarate (Tecfidera, Generic)
- Diroximel Fumarate (Vumerity)
- Fingolimod (Gilenya)
- Monomethyl Fumarate (Bafiertam)
- Ozanimod (Zeposia)
- Ponesimod (Ponvory)
- Siponimod (Mayzent)
- Teriflunomide (Aubagio)
- Hollen CW, Paz Soldán MM, Rinker JR, Spain RI. The Future of Progressive MS Therapies. Fed Pract. 2020 Apr;37(Suppl 1):S43-S49.
- Tortorice K, Antonovich N. MS Medications in the VHA: Delivering Specialty, High-Cost, Pharmacy Care in a National System. Fed Pract. 2020 Apr; 37(Suppl 1): S36–S42.
- AAN Practice Guideline Recommendations Summary: Disease-modifying Therapies for Adults with MS
- National MS Society Medications
Disclaimer: Links are provided as a convenience and for informational purposes only. They do not constitute an endorsement or an approval by MSCoE of any of the products, services, or opinions of the organization. MSCoE bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links. Contact the external site for answers to questions regarding its content.